Peptide profile
Pentadecapeptide BPC-157 (Oral Stable)
Oral-stable pentadecapeptide for GI repair
Compare Pentadecapeptide BPC-157 (Oral Stable) with other peptides →Summary
A swallowable BPC-157 that helps heal your tummy.
- Typical dose
- 250-500mcg 1-2x daily
- Route
- Oral
- Cycle length
- 30-90 days
- Evidence
- Animal data
Mechanism
How it works
Oral BPC-157 works like a swallowable repair kit for your gut — it travels intact through stomach acid to where it's needed, then directs healing along the whole digestive tract.
Oral BPC-157 is formulated to survive gastric acid, then binds to growth factor receptors in the GI tract, stimulating angiogenesis and tissue repair.
Reported in research
Benefits
- Heals sores in your stomach and gut
- Helps fix a leaky gut
- Calms swelling and soreness in your gut
- Protects your gut from pain medicine damage
Context, not a prescription
Dosing
- Typical range
- 250-500mcg 1-2x daily (Oral)
- Cycle length
- 30-90 days
Safety
Side effects & contraindications
Possible side effects
- Minimal GI discomfort initially
- Mild nausea (rare)
- Headache
- Dizziness
Contraindications
- Pregnancy or breastfeeding
- Active cancer
- Inflammatory bowel disease (limited data)
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Sores heal, your gut leaks less, and you feel less heartburn and soreness.
How it works
This pill is like a repair kit you can swallow. It travels safely through your stomach acid. Then it tells your whole gut where to heal.
It works with special helpers called VEGFR2 and FAK in your gut lining. These help cells move and grow to fix things.
What to expect
You feel better in a few days. Deeper healing takes 4-8 weeks.
- Days 1-3: Less heartburn and tummy pain.
- Weeks 2-3: Better digestion and less bloating.
- Weeks 4-8: Big healing of sores and gut repair.
Good to know
- Take it on an empty stomach
- Start with a small 250mcg amount
- Take breaks between use
Staying safe
- A little tummy upset at first
- Mild yucky feeling (rare)
Avoid if you have:
- Pregnant or breastfeeding moms
- People with cancer right now
- People with gut diseases (we don't know enough yet)
Mechanism of action
Oral BPC-157 is formulated to survive gastric acid, then binds to growth factor receptors in the GI tract, stimulating angiogenesis and tissue repair.
Interacts with the VEGFR2 and FAK pathways in intestinal epithelium, promoting cell migration and proliferation.
Pharmacodynamics
Within days for symptom relief; deeper healing over 4-8 weeks.
Healed ulcers, reduced gut permeability, less irritation and heartburn.
Timeline
- Days 1-3: Reduced heartburn and abdominal pain.
- Weeks 2-3: Improved digestion and less bloating.
- Weeks 4-8: Significant ulcer healing and barrier repair.
Comparisons
- BPC-157 Oral — effectiveness Moderate, safety Good, cost $$, Very Easy to use
- BPC-157 Injectable — effectiveness High, safety Good, cost $$, Medium to use
Adverse effects
Common:
- Minimal GI discomfort initially
- Mild nausea (rare)
Rare:
- Headache
- Dizziness
Contraindications & risk mitigation
Contraindicated in:
- Pregnancy or breastfeeding
- Active cancer
- Inflammatory bowel disease (limited data)
- Take on empty stomach
- Start with 250mcg dose
- Cycle with breaks
Qué hace
Las llagas sanan, tu intestino pierde menos permeabilidad y sientes menos acidez y malestar.
Cómo funciona
Esta pastilla es como un kit de reparación que puedes tragar. Viaja con seguridad a través del ácido de tu estómago. Luego le indica a todo tu intestino dónde necesita sanar.
Trabaja con ayudantes especiales llamados VEGFR2 y FAK en el revestimiento de tu intestino. Estos ayudan a que las células se muevan y crezcan para reparar las cosas.
Qué esperar
Te sentirás mejor en unos días. La cicatrización profunda tarda de 4 a 8 semanas.
- Días 1-3: Menos acidez y dolor de estómago.
- Semanas 2-3: Mejor digestión y menos hinchazón.
- Semanas 4-8: Gran cicatrización de llagas y reparación intestinal.
Bueno saber
- Tómala con el estómago vacío
- Comienza con una pequeña cantidad de 250 mcg
- Toma descansos entre los ciclos de uso
Manteniéndose seguro
- Un poco de malestar estomacal al principio
- Náuseas leves (raro)
Evitar si tienes:
- Mujeres embarazadas o en lactancia
- Personas con cáncer activo
- Personas con enfermedades intestinales (aún no sabemos suficiente)
Mecanismo de acción
El BPC-157 oral está formulado para sobrevivir al ácido gástrico, luego se une a los receptores de factores de crecimiento en el tracto gastrointestinal, estimulando la angiogénesis y la reparación tisular.
Interactúa con las vías VEGFR2 y FAK en el epitelio intestinal, promoviendo la migración y proliferación celular.
Farmacodinamia
Alivio de síntomas en días; cicatrización profunda en 4-8 semanas.
Úlceras curadas, menor permeabilidad intestinal, menos irritación y acidez estomacal.
Cronología
- Días 1-3: Menos acidez estomacal y dolor abdominal.
- Semanas 2-3: Mejor digestión y menos hinchazón.
- Semanas 4-8: Cicatrización significativa de úlceras y reparación de la barrera intestinal.
Comparaciones
- BPC-157 Oral — efectividad Moderada, seguridad Buena, costo $$, Muy fácil de usar
- BPC-157 Inyectable — efectividad Alta, seguridad Buena, costo $$, Media de usar
Efectos adversos
Comunes:
- Mínimo malestar gastrointestinal al inicio
- Náuseas leves (raro)
Raros:
- Dolor de cabeza
- Mareos
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Embarazo o lactancia
- Cáncer activo
- Enfermedad inflamatoria intestinal (datos limitados)
- Tomar en ayunas
- Comenzar con una dosis de 250 mcg
- Realizar ciclos con descansos
Reference data
Specifications
- Route
- Oral
- Cycle length
- 30-90 days
FAQ
Common questions
Is oral as effective as injectable?
Oral targets GI tract specifically; injectable works systemically (joints, muscles, nerves). For gut issues, oral is preferred.
Can I take it with food?
Best on empty stomach (30 min before meals or 2 hours after).
What is the evidence level?
This compound is classified as Animal data. Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.
Research
Research & sources
Current evidence for Pentadecapeptide BPC-157 (Oral Stable) is rated as Animal data. Research is based primarily on animal models.
- 1. BPC-157 stable gastric pentadecapeptide (2020) — DOI:10.3390/ph13090268
- 2. Oral BPC-157 GI healing (2014) — DOI:10.1016/j.peptides.2014.03.002
- 3. BPC-157 stable gastric pentadecapeptide (2020)
- 4. Oral BPC-157 GI healing (2014)